Top

Published in:

01-06-2009 | ORIGINAL RESEARCH

P53 Arg72Pro Polymorphism in Gastric Cancer Patients

Authors: Lessileia Gomes de Souza, Jacqueline Miranda de Lima, Ismael Dale Cotrim Guerreiro da Silva, Nora Manoukian Forones

Published in: Journal of Gastrointestinal Cancer | Issue 1-2/2009

Abstract

Introduction

Polymorphism in codon 72, exon 4 of p53 may alter apoptosis and cancer progression.

Patients and Methods

P53 Arg72Pro genotype was assessed by PCR from 84 gastric cancer patients and 185 controls. The control group was comparable in sex, race, age, smoking, and alcohol intake to the cancer group.

Results and Discussion

There was no difference among the frequency of the alleles or genotypes between the groups. P53 Pro/Pro was associated to a lower risk of metastatic disease (p = 0.02) but not to lymph nodes metastasis or worst prognosis. Arg/Arg or Arg/Pro genotype may be associated to metastatic disease.

The Brazilian National Cancer Institute. INCA. http://www.INCA.org.br.

National Center for Health Statistics. Canters for disease control and prevention: US mortality public use data tapes. 1969–2003. http://seer.cancer.gov

Elkabawy M, Maxwell P, Williamson K, et al. Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival. J Pathol. 2001;194:436–43.CrossRef

Etienne MC, Chazal M, Laurent-Puig P, et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol. 2002;20(12):2832–43.PubMedCrossRef

Lane D. Cance. P53, guardian of the genome. Nature. 1992;358:15–6.PubMedCrossRef

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.PubMedCrossRef

Soussi T, Béroud C. Assessing TP53 status in human tumors to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233–40.PubMedCrossRef

Dumont P, Leu JI, Della Pietra AC 3, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.PubMedCrossRef

Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet. 2006;38(10):1133–41.PubMedCrossRef

10.

Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29:697–702.PubMedCrossRef

11.

Milner J. Flexibility: the key to p53 function? Trends Biochem Sci. 1995;20:49–51.PubMedCrossRef

12.

Hoe YJ, Cho HM, Chin HM, Kim W, Jeon HM. Gastric cancer susceptibility in the p53 codon 72 polymorphism. J Korean Surg Soc. 2005;69:24–30.

13.

Bae DH, Kim JS, Choi SD, Sunwoo JG, Nam KH, Kim CJ. Human papillomavirus infection and polymorphism of p53 codon 72 in the uterine cervical neoplasia. Korean J Gynecol Oncol. 2003;14:281–9.

14.

Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–100.PubMed

15.

Zhang ZW, Newcomb P, Hollowood A, Feakins R, Moorghen M, Storey A, et al. Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res. 2003;9:2151–6.PubMed

16.

Mader AM, Patrício FR, Rigueiro MP, Lourenço LG. Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cárdia. Arq Gastroenterol. 2006;43(3):184–90.PubMedCrossRef

17.

Xi YG, Ding KY, Su XL, Chen DF, You WC, Shen Y, et al. P53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis. 2004;25:2201–6.PubMedCrossRef

18.

Szöke D, Molnár B, Solymosis N, Sipos F, Galamb O, Györffy A, et al. The RR genotype of codon 72 of p53 gene reduces the development of intestinal metaplasia. Dig Liver Dis. 2008;. doi:10.1016/j.dld.2008.04.005.PubMed

19.

Perez-Perez GI, Bosques-Padilla FJ, Crosatti ML, Tijerina-Menchaca R, Garza-Gonzalez E. R53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol. 2005;40:56–60.PubMedCrossRef

20.

Yi SY, Lee WJ. A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol. 2006;12(40):6536–653.PubMed

21.

Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis. 2007;28:1996–2001.PubMedCrossRef

22.

Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121(7):1481–6.PubMedCrossRef

23.

Alpízar-Alpízar W, Sierra R, Cuenca P, Une PC, Une C, Mena P, et al. Association of the p53 codon 72 polymorphism in gastric cancer risk in a high risk population of Costa Rica. Rev Biol Trop. 2005;53:317–24.PubMed

24.

Lai KC, Chen WC, Tsai FJ, Li SY, Jeng LB. Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology. 2005;52(63):944–8.PubMed

Title: P53 Arg72Pro Polymorphism in Gastric Cancer Patients
Authors: Lessileia Gomes de Souza
Jacqueline Miranda de Lima
Ismael Dale Cotrim Guerreiro da Silva
Nora Manoukian Forones
Publication date: 01-06-2009
Publisher: Humana Press Inc
Published in: Journal of Gastrointestinal Cancer / Issue 1-2/2009
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-009-9078-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Patients and Methods

Results and Discussion

Please log in to get access to this content

Other articles of this Issue 1-2/2009

Primary Gastric Leiomyosarcoma in Young Revealed by a Massive Hematemesis

Cholangiocarcinoma in Primary Sclerosing Cholangitis

Multifocal Epitheloid Hemangioendothelioma of Liver after Long-Term Oral Contraceptive Use—A Case Report and Discussion of Management Difficulties Encountered

Rare Natural Killer Cell Lymphoma Found During Surveillance Endoscopy

Cumulative Morbidity and Late Mortality in Long-Term Survivors of Exocrine Pancreas Cancer

Large Mass Affecting Retroperitoneal Great Vessels: A Rare Presentation of A Cancer of Unknown Primary with Diagnostic Dilemma and Challenged Surgical Intervention

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials